最新临床试验：纳武单抗治疗肾切除术后局部肾癌

这是一项随机对照III期临床试验，目的是比较肾切除（切除肾脏或部分肾脏的手术）后，联合或不联合使用纳武单抗治疗肾癌（局限于身体的某一部分）患者的疗效。单克隆抗体的免疫治疗，如纳武单抗，可以帮助身体的免疫系统攻击癌症，并可能干扰肿瘤细胞的生长和扩散的能力。在肾切除术前给予纳武单抗可使肿瘤变小，减少需要切除的正常组织的数量，在肾切除术后给予纳武单抗可增加存活率。目前尚不清楚在治疗肾癌患者中，纳武单抗和肾切除术联用是否比单纯肾切除术更有效。

本临床试验正在全美243家医院开展！

This randomized phase III trial compares nephrectomy (surgery to remove a kidney or part of a kidney) with or without nivolumab in treating patients with kidney cancer that is limited to a certain part of the body (localized). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving nivolumab before nephrectomy may make the tumor smaller and reduce the amount of normal tissue that needs to be removed, and after nephrectomy to increase survival. It is not yet known whether nivolumab and nephrectomy is more effective than nephrectomy alone in treating patients with kidney cancer.

Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 243 locations